key: cord-1056442-foaceqe3
authors: nan
title: COVID-19
date: 2022-03-03
journal: Lung India
DOI: 10.4103/0970-2113.341088
sha: eb9fd3bfb5292e57d956bdf8ea872a1e786bf0fb
doc_id: 1056442
cord_uid: foaceqe3

nan

Interventional Pulmonology and Respiratory medicine, Naruvi Hospitals, Vellore, Tamil Nadu, India. E-mail: vimi.v@ naruvihospitals.com, viminvarghese@gmail.com Background: REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike protein, and thus stops the progression of disease. We aim to evaluate the safety and efficacy of REGEN COV in patients presenting with Mild to moderate Covid 19 disease. Methodology: This is a retrospective observational study done in a tertiary hospital in South India. Patients admitted with RTPCR confirmed SARS COV 2 infection and within 10 days of symptoms onset were included in the trial. All patients received 1,200 mg each of casirivimab and imdevimab as a single intravenous infusion. All the patients were followed up for a period of 30 days with weekly telephonic consultation. Results: Between June 1 , 2021 and October 15 ,2021 , 30 patients got enrolled into the study and the mean age of patients was 60 years. The median duration from symptom onset to Regen Cov treatment was 5 days. Only 2 (10%) patients had adverse events and 83% of patients (25/30) had no symptoms after Regen Cov administration and 86% of patients (26/30) had no progression of clinical symptoms for up to 30 days after discharge. Conclusion: The monoclonal antibody combination of casirivimab and imdevimab (REGEN-COV) successfully prevented the progression of disease in 86% of patients presented with mild to moderate COVID 19 disease. Our study also underlined the safety of Regen Cov treatment with no major adverse event occurred in any of the patients.

LDH and hsCRP levels done on the day of admission. The total CT score was the sum of five individual lobar scores and defined as: 0, none; 1-5, minimal; 6-10, mild; 11-15, moderate; and 16-20, severe lung involvement. Results: Mean age of 240 (Male 156 and Female 84) study sample was 52.42 years (SD -15.28) with maximum 87 years & minimum 20 years old. As per WHO COVID-19 Clinical Management Guidelines, 180 (75%) patients with Non severe, 31 (12.9%) patients with Severe and 29 (12.1%) patients were having Critical clinical presentation on admission. hsCRP & LDH were having more correlation coefficient than other markers with CT score (0.599 & 0.570 respectively). Conclusion: hsCRP and LDH levels can be used to predict extent of lung involvement in COVID-19 disease especially in resource limited settings.

Background: We report a rare case of solitary peripheral pulmonary artery aneurysm in a patient who was evaluated for haemoptysis. Incidentally, his total antibodies were positive for Coronavirus 2019 infection. Patient underwent right lower lobectomy uneventfully. Peripheral pulmonary artery aneurysms arising from segmental or intrapulmonary branches are extremely rare. Untreated, the majority end fatally due to sudden rupture and exsanguination. The purpose of this article is to report our rare case and review the pertinent literature. Case Study: A 40-year-old man presented with an episode of haemoptysis. He had a history of intermittent mild grade fever, cough and dyspnea lasting for a month. He had no history of haemoptysis in the past. He had no pre-existing medical conditions or Coronavirus 2019 (COVID-19) infection. His clinical examination was unremarkable. Blood investigations were within normal limits. Reverse transcription polymerase chain reaction test was negative for COVID-19 infection, but his total antibodies test was elevated -117 (biologicalreference range <1.0). 2D Echocardiography was normal. Chest radiography showed a solitary pulmonary lesion in the right lower lung zone [ Figure 1a ].A computed tomography of the chest plain and contrast confirmed the presence of a 3.7 cm_3.6 cm, well-defined, circumscribed and densely enhancing lesion in apicoposterior segment of right lower lobe. It is seen along the course of descending branch of the right pulmonary artery. Areas of consolidation are also seen in apicoposterior segment. Postcontrast study shows heterogenous enhancement of this lesion suggestive of an aneurysm. The rest of lung parenchyma was normal [ Figure  1b and c].The diagnosis of a solitary peripheral pulmonary artery aneurysm (PAA) was considered and right lower lobectomy was performed through posterolateral thoracotomy. Discussion: The estimated incidence of PAA is 1 in 14 000 autopsies, and these lesions can be central aneurysms and peripheral aneurysm. An aneurysm can be true or pseudo aneurysm. In this patient, an aneurysm is a true aneurysm and origin may be idiopathic or post-inflammatory with superadded fungal infection in thrombus, post-COVID-19 infection. Long-term follow up is required to observe the future course Conclusion: True solitary peripheral PAA is an extremely rare entity. A high degree of suspicion is needed for diagnosing PAAs on imaging. Intervention is mandatory as soon as the diagnosis is made, to prevent rupture and death. PAA has been managed most often by lobectomy but occasionally by pulmonary artery repair or endovascular approach.

areas. Clinical data such as the duration of exposure to Covid patients, presence of comorbid illnesses, vaccination against COVID-19, need for admission and treatment received were collected. The study period is from May 2020 -August 2021, the data was collected using a crosssectional, interviewer administered questionnaire. Blood samples for measuring Immunoglobulin levels were collected in 5 different time periods. Results: 299 people were included in the study, 89% were high risk HCW and 11% low risk HCW. 39.7% of the high risk HCWs tested positive for Covid-19 as opposed to 9% of low risk HCWs. 46.2% and 50% of high and low risk HCWs received vaccination prior to testing positive for COVID-19. There was no significant difference in home isolation or hospital admission rates between the two groups. Only 1 High risk HCW required Oxygen with no mortality. High risk HCW had higher Nucleocapsid antibody positivity. Conclusion: Absolute risk reduction of confirmed Covid-19 between high and low risk HCWs was 84.2%. Factors such as age, gender, workplace exposure, seniority of staff and comorbidity did not affect seropositivity rates. Following strict infection prevention and control measures and vaccination helped decrease severe illness.

Aim: During Covid-19 pandemic outburst hospitals were categorised to manage patients as per severity of disease. At Level-2 hospitals which were equipped with Oxygen and NIV requirements, patients with moderate severity were kept. This study aims to statistically analyse patients admitted during 2 nd phase of Covid-19. Aim is to understand factors involved in recovery of such patients. Methods: During study, symptoms, CT score, requirements of NIV, Oxygen Flow and Demographic details were recorded. During recovery phase, PFT, 6MWDT and residual symptoms were analysed. For this study, 30 patients between 38-65 years of age, admitted between April-June 2021 and followed for next four months were enrolled.

It was observed: a. 50% of patients were having comorbidities, DM Type2 was common b. Fever and breathlessness were common symptoms c. As per CT score a. 80% of patients had moderate to severe lung involvement b. Higher CT score, lower was 6MWDT value (p0.45) c. Days of hospitalization and recovery time were not related d. PFT Early changes may present radiologically as traction bronchiectasis, architectural lung distortion, crazy paving or thickened interlobular septa. Analogy from other fibrotic interstitial pneumonia suggest up regulation of TGF B, FGF and PDGF leading to lung fibrosis (1) . Early data of post covid 19 pneumonia shows a residual restrictive pattern on pulmonary function testing (2). Also radiological persistence of GGO has been observed (3). The autopsy studies from acute COVID 19 pneumonia has demonstrated feature of Diffuse Alveolar Damage (DAD) and fibrotic organising pneumonia (4). The epidemics of SARS and MERS showed similar features, suggestive of developing lung fibrosis (5). The present study is designed to study the clinical and CT radiographic patterns at presentation and their outcome on follow up, which will enhance our current understanding of covid 19 manifestations and outcome with this prospective observational study. Methods: The CT scans (admission & 4-8 weeks follow up) were collected from Medanta the Medicity, and deidentified in the local image archive system (PACS). Three chest radiologists with > 15 years of experience, from three tertiary care centres performed independent reporting of the CT scans, to pre-specified radiologic criteria. They were blinded to the clinical severity of disease. For the reading process, the radiologists reviewed the cases online via screen sharing (Zoom). Results: A composite score of the density of lesions and the extent of lung involvement has been proposed to provide a more comprehensive picture of the radiological severity and its impact on clinical severity and outcome of disease.

Final result yet to be analyzed.

Background: The COVID-19 pandemic is an ongoing global health care challenge. Upto 1/3rd of hospitalised patients develop severe pulmonary complications and ARDS. Our study aims to evaluate the pulmonary function in COVID-19 pneumonia patients at 6 months follow up. Methods: Prospective cohort study in 30 hospitalised patients with a confirmed diagnosis of COVID-19 pneumonia; belonging to mild, moderated, severe categories -6 months after discharge. The study consists of assessing the pulmonary function with pre and post bronchodilator spirometry and 6-minute walking test for post exercise desaturation. Results: Lung function test results showed 27% patients had a normal FEV1/FVC ratio with reduction in FVC (forced vital capacity). The mean basal saturation before the 6-MWT was 96+ or -2%. Exercise oxygen desaturation was observed in 6% cases. Conclusion: This study shows that post infection with SARS-CoV-2, severe or critical covid-19 pneumonia patients showed higher prevalence of abnormal spirometry , with a mainly restrictive pattern when compared to non severe pneumonia patients.

Akkupalli Sreekanthyadav, B. Neeharika, P. Yugandhar E-mail: 1994sreekanth1994@gmail.com Background: There is a great uncertainty on disease progression in covid-19. Multiple factors play a role in progression of disease to severe form and these factors are not uniform in all patients. There are multiple researches for the early prediction of outcome using various prognostic factors. Methods: Data of 112 patients from ASRAM medical college was collected retrospectively. The clinical parameters like age, gender, oxygen saturation and comorbidities at the time of admission, lab parameters like Neutrophil-Lymphocyte Ratio (NLR) and radiological parameters like CT severity score were taken. This data was analyzed to predict the association with mortality. Results: These 112 patients consisted of age ranging from 20-90 years. Males were 70(62.5%) and females were 42 (37.5%). Mortality was more in the age group of 61-80, that is 13 deaths (40.6%) (p= 0.023). Higher mortality was seen in patients with oxygen saturation less than 90%, deaths 25(35.2%) (p=0.001). Mortality was more in patients with comorbidities (66.7%) (p=0.000). Number of deaths in patients with NLR more than 3.5 were 25(27.2%) (p=0.01). Patients with CT severity score more than 15 had higher mortality (44.2%) (p=0.000). Conclusion: Though CT severity score is a good predictor of mortality in patients with covid-19, initial assessment of patients for clinical parameters like age, oxygen saturation, comorbidities and easily available laboratory parameter like NLR are also good predictors of mortality and severe form of disease.

Background: Neutralizing antibodies cocktail (Casirivimab and Imdevimab) has received conditional recommendation by FDA and WHO for mild to moderate COVID infection in specific high-risk groups. Persons with underlying chronic illnesses are at high risk of developing severe disease. The effectiveness of various repurposed drugs approved for the management is variable. Antibodies cocktail has shown promising results in preventing progression to severe disease. But the data about its use and safety from India is scarce. Herein, we present a retrospective analysis of 10 patients who were administered with the antibodies cocktail between Aug 2021 and Oct 2021. Methodology: We conducted an observational retrospective analysis of clinico-radiological, inflammatory parameters, progression of the disease, and outcome amongst ten mild and moderate COVID 19 patients treated with antibodies cocktail. Results: Ten patients were administered the antibodies cocktail (casirivimab 600 mg and Imdevimab 600 mg). The median age was 63.5 years, and four patients were partially vaccinated, and the rest were unvaccinated. Diabetes and hypertension were the commonest comorbidities; hematological and solid organ malignancies were other comorbidities. The median CRP level on admission was 91.5 mg/dL. Other inflammatory markers like neutrophil: lymphocytes ratio, ferritin, and LDH were higher than normal limits. None of our patients required supplemental oxygen or progressed to severe ARDS nor has any adverse reactions. All patients were discharged in a stable condition within six days of the therapy. Four patients had radiological opacities consistent with COVID 19 pneumonia and had shown regression after the therapy. The observation indicates that this therapy may also be effective in the early pulmonary phase of the disease. Conclusions: The neutralizing antibodies cocktail has shown encouraging results in our analysis in preventing progression to severe disease and is not associated with severe adverse reaction.

Medanta The Medicity, Gurugram, Haryana, India. E-mail: spaharia88@gmail.com Introduction: Coronavirus disease-19 (COVID-19)has become a global pandemic, giving rise to a serious health threat worldwide. So far, several countries have seen a two-wave pattern of reported cases. Methodology: This was a retrospective study of all hospitalized cases of SARS-CoV-2. All the patients admitted between March to December 2020 were considered to be in first wave and those admitted from April to June 2021were considered to be in second wave. All hospitalized patients had SARS-CoV-2 infection confirmed by RT-PCR. Results and Discussion: Total 4581 patients in first wave & 1565 in second wavetested positive for SARS-CoV-2 infection using RT-PCR at the hospital.In the first wave highest admissions occurred in the month of November 2020. In the second wave, the highest admissions occurred in the month of April 2021. In first wave 71% were male and 29% were female while in second wave 67% male and 33% were female. The mean age of first and second wave was 54.9±16.6 and 55.2±15.5. CT severity scores were 18.8±9.9 in wave 1 versus 21.4±10.4 in wave 2.(p=0.0001)A total of 54 (1.2%) deaths occurred in the first wave and 26 (1.7%) in the second wave. Conclusion: Lung involvement on CT scan was more extensive in wave 2 compared to wave. A large number of patients were admitted during the second wave, they were younger and fewer number of deaths was reported corresponding with results reported by previous research in several countries. protocol. The chest x-ray, blood investigation and sputum investigation were studied till the time of discharge or death. Results: Out of 323 patients studied 14 had Tuberculosis. Out of those 14 patients 10 patient had pulmonary tuberculosis, 3 had Tuberculous pleural effusion and one had abdominal tuberculosis. All of them had pneumonia on chest x-ray which can be attributed to covid-19 or Tuberculosis.

In our study all 14 patients were survived and discharged. As there is high burden of tuberculosis the covid-19 only helped in exposing the tip of the iceberg of the grave problem of undiagnosed tuberculosis in community. It seems that there is just coincidental occurrence of tuberculosis and covid19 coinfection than a causal association. However, 142 patients (88.75%) were found to be without any co-morbidities.17 patients (10.6%) developed symptoms on 3 rd day whereas 7.5%, 6.8%, 3.7% and 1.2% became symptomatic on 2 nd , 4 th , 1 st and 5 th day respectively. Conclusion: Cough was the most common symptom seen followed by fever, sore throat, generalized weakness and dyspnea. Asymptomatic patients were mostly without any comorbidities and hence remained asymptomatic and overall outcome was better.

Background: COVID-19, an infectious disease caused by SARS-CoV-2 virus has reported to be a global pandemic. About 5% of the total develop severe ARDS. Aim: To study the clinical profile, comorbidities and outcome including mortality rate in severe Covid-19 ARDS patients. Methodology: 40 cases of severe COVID 19 infection (P/F ratio<300) admitted in tertiary care ICU treated with standard covid protocol were included in the study. Their demography, severity of hypoxia, mode of ventilation and outcome analysed. Re s u l t s : O u t o f t h e 4 0 p a t i e n t s a d m i t t e d , 2 9 (72%) were discharged with 11 patients (38%) requiring home oxygen therapy. The most common comorbidities were diabetes mellitus (30%) and hypertension (22.5%). Mean hospital stay was 17 days, and 35 patients (87.5%) required ventilation of which 80% on NIV and 20% on Mechanical ventilation. The mortality rate was 27.5%. The P/F ratio and CRP values was statistically significant with mortality rate (p-value<0.05). Three patients (7.5%) on positive pressure ventilation developed pneumothorax. One patient (2.5%) developed pulmonary thromboembolism.14 patients (35%) were in MODS out of which 8 patients died. Conclusion: Mortality rate was less in patients with a high P/F ratio and low CRP levels at the time of admission. Severe COVID 19 patients admitted in the ICU had developed additional complications requiring interventions. Patients in MODS had high mortality rate. Most common comorbidity associated was diabetes mellitus. Of these, 60% (40) had comorbidities. The major co-morbidities in dead patients were diabetes (33.33%) followed by hypertension (24.2%). In patients with underlying respiratory diseases, COPD (12.1%) was followed by Post Tuberculosis OAD (3%) and Tuberculosis (3%). As compared with the First Covid wave, the Second wave had a mortality of 48.5% (47). The major co-morbidities in dead patients were hypertension (38.3%) followed by diabetes (25.5%). In patients with underlying respiratory diseases, COPD (4.3%) was the most common cause of death. Conclusion: In both the Covid waves, diabetes, hypertension and COPD (underlying respiratory disease) were the leading co-morbidities associated with death. Background: Mucormycosis is an invasive-fungal infection, often associated with extremely severe complications in immuno-compromised patients. The prevalence of mucormycosis in India is about 80 times higher than other developed countries. But the clinical presentation of pulmonary mucormycosis has wide diversity. Case Study: We are reporting a case of a 45-year-old man admitted to our side as a case of post-COVID sequelae in the setting of a new left sided loculated pyo-pneumothorax. He is a known case of type 2 diabetes and hypothyroidism for 1.5 years and 3 years respectively. Prior to our rescue, he underwent pigtail insertion in the loculated collection, but there was no output. So, the drain was removed and the patient was planned for pneumonectomy. On visiting to our side, appropriate investigation and interventions were done. On bronchoscopy a large fungating fragile blackish growth was seen coming out from left main bronchus. Histopathological report of the endobronchial biopsy revealed mucormycosis. The patient was planned for Liposomal Amphotericin-B (LAMB) but unfortunately developed anaphylaxis. He was managed accordingly and was taken on oral Posaconazole therapy. On follow up visit remarkable clinical and radiological improvement was noted. Discussion: The above-mentioned case showed the management of a not so mimicking case of usual pulmonary mucormycosis without opting for surgical intervention. Thus, limiting the patient from the postsurgical complications. Conclusion: This case illustrates the heterogeneousness of mucormycosis, regardless of patient profile. Bronchoscopic findings and mycology report helped us to rule out other differential diagnosis.

Background: Development of spontaneous pneumothorax and pneumomediastinum is one of the complication of COVID-19 viral pneumonitis. This has been described in both mechanically ventilated patients or on non invasive/ high flow nasal cannula oxygen support. The Macklin effect can been proposed as a possible etiology owing to the propensity to the damage to type2 pneumocytes, alveolar rupture secondary to direct alveolar injury. Case: 32 year male, non smoker, non alcoholic with no comorbidities presented to emergency with sudden onset of shortness of breath, left chest pain. HRCT chest done showed left pneumothorax with mediastinal shift. Intercostal drainage tube(ICD) was placed on the left side and patient was stabilised. Patient has had similar complaints one week back for which right sided ICD was placed. Patient had history of COVID-19 infection one month back. He did not require any supplemental oxygen or ventilatory support. Right side ICD was removed 1 week later as there was no air leak. Left side had persistent air leak, with non expanding lung. Patient was put on supplemental oxygen. He was treated with antibiotics, other supplemental oxygen and repeat HRCT chest showed loculated hydropneumothorax with bronchopleural fistula (BPF) on the left side. The patient was discharge with ICD. After improving the general condition, the air leak was surgically corrected with left lobe decortication and BPF closure. Conclusion: COVID 19 infection renders more propensity to damage type 2 pneumocytes. The alveolar rupture is secondary to alveolar injury causing increased tendency for air leak without obviously increased pressures.

Background: COVID-19 pandemic has affected majorly the lungs besides many other organs. Many of the patients later developed pulmonary-fibrosis. This study was planned to know the determinants resulting in pulmonary-fibrosis in post COVID survivors. Methods: Hospital-based, cross-sectional study done over a period of one year. A pre-designed proforma used to collect necessary information and follow-up HRCT and other investigations were evaluated. Results: Out of 87 patients 41.3% (n=36) developed pulmonary fibrosis among which majority i.e., 66.6% (n=24) were males. Out of 87 patient 49.42% (n=43) belonged to the age group of 51-70 years among which 48.83% (n=21) developed fibrosis. Infection was more common in urban 63.2% (n=55), middle-class family 55.17% (n=48), non-smoker 65.51% (n=57), homemaker and office worker 49.4% (n=43). Out of 87 patients 57.47% (n=50) had different comorbidities out of which 52% (n=26) developed pulmonary fibrosis. The proportion of fibrosis among diabetic patients was 67.7% (n=21, p=0.036). A total of 27 patients were treated in ICU, out of which 66.67% (n=18) developed pulmonary fibrosis. About 57.14% (n=28) of the patient with leucocytosis developed pulmonary fibrosis. Pulmonary fibrosis developed more in which steroid are not used 9/19, 47% (n=9) compared to those where was steroid used 27/68, 39.7% (n=27). Majority of the patient i.e.,>90% fibrotic patient had raised inflammatory marker. Higher CT severity score and consolidation are predictive for post covid fibrosis Conclusion: Post-COVID-19 pulmonary-fibrosis was observed in about half of the survivors. This study emphasized the relation of pulmonary-fibrosis with many factors like age, comorbidities, ICU-admission, steroid usage, inflammatory-markers and secondary-infections.

We estimated levels of oxidative stress biomarkers (Lipid peroxidation (LPO) via Malondialdehyde MDA concentration , Superoxide dismutase (SOD), Glutathione Reductase (GR) and Total antioxidant activity (TAA) in patients who were symptomatic beyond 4 weeks of COVID infection.

It's a single centre, hospital based case control study in which levels of oxidative stress biomarkers in 40 Long COVID patients and 40 healthy controls were compared and analysed with their clinico-radiological profile. inversely proportional to the Severity of COVID and Xray Severity score 6. The patients with added comorbidities showed even higher oxidative stress than those with no comorbidities (p value 0.05) 7. Lipid peroxidation was significantly high in patients who developed neurological sequelae after COVID infection (p value 0.0083). Conclusion: A subset of patients develop a sequelae to COVID infection and in those patients oxidative stress plays a major role. Email: anjaliparhar@gmail.com Background: 35yrs female, without comorbidities hospitalised in emergency in icu due to sudden severe breathlessness and chest pain, fever, weakness, cold, throat pain, vomiiting of 4 to 5 days duration. Case Study: H/o 1st dose covid vaccination received 4 to 5 days ago. Latest COVID RT-PCR negative. Patient required o2 support as her Spo2 on admission was 87%.All necessary lab done. 2DECHO done by cardiologist s/o moderate pericardial effusion causing temponade, also dilated RA/ RV, RV dysfunction, septal buging s/o effussion/constrictive pericarditis. Hence emergency pericardiocentesis was done under fluroscopic guidence. 500ml pale yellow fluid aspirated and pigtail was placed. Fluid was sent for testing. It showed on Gene Xpert detection of mycobacterium tuberculosis and no resistance to rifampicin. Pulmonary embolism and other systemic causes of pericardial effusion ruled out. Patient gave history of Miliary tuberculosis and completed treatment 1 month ago with HRCT chest after treatment completed showing normal lung parenchyama. All symptoms started on the day of vaccination in evening. She also had associated bilateral moderate pleural effusion L>>R. Left sided pleural fluid tapping done and sent for examination. Pt was started on 1st line anti-TB drugs along with diuretics, steroids. She responded well to treatment. Subsequent follow up 2DECHO screening and CXR showed resolution of effusion. Pigtail pericardial catheter removed, O2 tapered off and patient discharged home. Called for follow up after 1 week for 2DECHO screening. Pericardial fluid TB liquid culture was sent which showed no growth after 8 weeks. Discussion: Reactivation of tuberculosis doesn't occur in all cases who has received covid-19 vaccination but we noted in 1 of our case. Conclusion: Reactivation of tuberculosis causing life threatning complication post COVID-19 vaccination.

Background: Post COVID -19 infection has wide range of presentation, cavitation and fungal infections were very common in these patients especially when they are immune compromised. This is a case study of a post covid patient with cavitary consolidation and Rasmussen's aneurysm secondary to invasive aspergillus infection. Case Study: A 62 year old gentleman, hypertensive, diabetic and survivor of severe COVID-19 infection presented with low grade fever, breathlessness and cough with expectoration. The CT scan showed bilateral cavitary consolidation . Sputum examination showed aspergillus growth and MTB negative. Serum galactomannan was positive. While getting treated with antifungal therapy for invasive aspergillus infection, he had one episode of massive haemoptysis. CT angiography showed Rasmussen aneurysm and planned for bronchial artery embolization. But the patient was not willing for any urgent intervention and got discharged on request after stabilisation, warning signs were explained. After 5 days patient had massive haemoptysis followed by circulatory collapse. Patient could not be saved even after resuscitation measures and emergency intubation. Discussion: Rasmussen's aneurysm is a pseudo-aneurysmal dilatation of a branch of pulmonary artery secondary to chronic inflammation in a contiguous cavity. The reported incidence of such pathology is around 5% in cavitary lesions. It may ruptures into the cavity, producing massive haemoptysis. Conclusion: Rasmussen aneurysm itself is a very dangerous entity irrespective of its etiology. Early interventions to prevent the fatal haemoptysis is the management strategy as conservative treatment may not give us enough time to act at the time of emergency.

Ex-HOD HEC Hospital, Ranchi, Jharkhand, India. Email: vermadrak@gmail.com

As of December 2021, India has over 34.8 million cases of COVID 19, an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has been a massive problem to society with variable manifestations in human, and there has been numerous reported cases of covid 19 patients presenting with broad spectrum of cardiovascular (CV) manifestations. This case abstract presented 3 patients with CV complication of COVID 19 leading to vascular ischemia, cardiac tamponade and ST elevated myocardial infarction All patients presented with chief complaint of high grade fever and shortness of breath. The first patient was a healthy and young 24-year-old male having pain in the right thigh with swelling. Doppler ultrasound of limbs showed poor venous flow indicating vascular ischemia. 2 nd patient was 60-year-old women with upper respiratory symptoms diagnosed with Covid 19 and had progressive dyspnoea. She was found to have a hemorrhagic pericardial effusion with echocardiographic signs of tamponade and grade 2 cardiomegaly. Third patient was a 59 years old diabetic male diagnosed with ST elevated myocardial infraction represented by elevated cardiac enzymes, raised troponin I, ST elevation in anterior and septal leads and akinesia in the region of left anterior descending coronary artery (LAD). Covid 19 infection has common respiratory foot prints identified by knowledge of clinical presentation however, it has also extra-pulmonary cardiac and Vascular Stigmas which can be of serious consequences. COVID-19 patients were enrolled. Clinical characteristics and comorbidities were assessed. Results: Of the 142 patients, 92(64.8%) were male, with a mean age of (56.00±14.81)years. The patients were elderly above 60(n = 62,43.7%) and adults (n = 80). Of these, 92 (64.7%) had comorbidities. Patients with severe COVID pneumonia 102(71.8%)were admitted to the intensive care unit (ICU), and 12(8.5%) patients have died. On admission, the main clinical manifestations were Fever (90.1%), dyspnea (83.8%), cough (78.2%), Anosmia (19%),alteration of taste (13.4%), haemoptysis (10.6%),headache (5.6%) and conjunctivitis (3.5%). Common comorbidities were diabetes mellitus(42.3%),hypertension (27.5%),Obesity (10.6%),heart failure (6.3%),COPD (3.5%),Asthma (2.5%),coronary artery disease (2.1%), ILD (2.1%),Post tubercular (1.4%),and CKD,CLD less than one perent.19% patients had history of contact COVID 19 cases. Smoking was present in 8.5% of cases. One comorbidity has been seen in 46, two in 28, and more than two in 5 patients. Patients were divided into four groups: no comorbidities, one comorbidity, two comorbidities, and more than two comorbidities. ANOVA test was used and showed that the value of serum creatinine (p=.017), serum bilirubin (p=.006), and serum SGOT (P=.009) were significantly associated. Conclusion: Severe COVID 19 disease had the worst outcome. In addition, serum creatinine and serum bilirubin values differed significantly in different comorbidities groups.

Background: Covid -19disease is a heterogeneous disease but most common presentation being due to involvement of respiratory system. Most patients experience mild illness and spontaneous recovery but some require hospitalization for pneumonia and other complications. This study aimed to evaluate the pulmonary sequel after covid-19 infection. Methods: Prospective observational study from tertiary care hospital. Both out and inpatients between April 2021 and May 2021 were enrolled. All were followed up at 3 and 6 months with CXR or HRCT chest and spirometry, exercise desaturation to assess residual parenchymal and functional impairment. Results: A total of 322 cases (mild-137, moderate-77, severe-108) were followed for 6 months following covid-19 infection. Mean age of patients was 47.48 +/-14.58. The mean CT scores of mild, moderate and severe cases were 4.49+/-1.5, 11.26+/-1.9, 18+/-2.3 respectively. Mean SPO2 scores 97.6+/-0.9, 91.6+/-3.4 and 84.6+/-5.9 respectively. At 3 month follow up in mild and most of the moderate cases no parenchymal residual or functional impairments. In severe cases at 3 months 66%, at 6 months 22% had residual parenchymal abnormalities. Restrictive functional impairment observed at 3 months in severe cases but at 6 months significant difference between mild, moderate and severe cases with mild restrictive impairment in severe cases. The sequel observed in severe cases were, lung fibrosis (22%), secondary bacterial infections (2.7%), PTB (2.7%), Mucor mycosis (1.8%), deaths (6.4%). Background: Pulmonary Mucormycosis was rare pulmonary fungal disease ,which was difficult to diagnose early and lack effective treatment but during COVID-19 pandemic the testing modalities have become handy , usually it used to occur in immune compromised patients , present days post Covid pulmonary mucor has become common. Case Study: A case of 60yrs old male patient , hypertensive, post Covid presented with cough associated with black coloured sputum, also with streaky haemoptysis and sob on exertion ,CT chest revealed left upper lobe thick walled cavity with reverse halo sign with lower septated cavity , with post covid lung fibrosis. Discussion: Pulmonary Mucormycosis may develop by inhalation of spores or by hematogenous or lymphatic spread, mostly seen in immune compromised patient, the sequelae include angioinvasion and direct tissue injury it may cause severe morbidity and mortality sputum and BAL cultures and radiological investigations are the crucial modalities for diagnosis sputum and BAL cytology may be inconclusive however early diagnosis will prevent the patient from life threatening complications and at times alternative drugs in unavoidable situations can prevent patient from life threatening complications. Conclusion: Different scenarios may be challenging. 

Background: In the wake of rise in COVID patients in the country, world is experiencing an acute shortage of mechanical ventilators and medical oxygen to an extent that many hypoxic patients are not able to get oxygen support. The need of the hour is a more efficient Oxygen Delivery device which can be easily accessible to most of remote health setups that are devoid of ICU beds or Ventilators. Moreover with the growing Oxygen Crisis, we also need devices that can help in Oxygen conservation. Objective: To assess the efficiency of bains circuit compared to NRBM in covid -19 patients awaiting NIV support based on SpO2 and PaO2. Methodology: Prospective study conducted on patients presenting with moderate to severe COVID 19 Disease. The study subjects will be randomly assigned to the experimental group. Baseline data (spO2 levels, PaO2 levels) will be collected, the experimental group will be Oxygenated via NRBM then shifted to Bains Circuit on same oxygen flow rates. SpO2 and PaO2 levels will be compared in the same group. Also, the total Oxygen consumption by each patient of same group will be compared.Assuming acute shortage of Oxygen, ventilator beds and ICU beds in most parts of India, the use of Bains Circuit, if proven efficient over NRBM can be a major help to most of the rural and low resource setups. It can be a useful device for transportation of severely hypoxic patients to higher DCHCs. Results: A common trend was seen in patients maintaining sufficient respiratory efforts but reduced SpO2 on NRBM, as soon as shifted on Bain's circuit (connected via a BiPaP mask), a sudden jump in SpO2 and PaO2 (approx. 15-20%) was seen at same oxygen flow rates. Conclusion: As we anticipate 3rd wave of Covid 19, keeping Bain's circuit as choice for oxygen therapy can be a lifesaving alternative for patients awaiting non invasive ventilator support.

Department of Pulmonary Medicine, Dr. SN Medical College, Jodhpur, Rajasthan, India. E-mail: thatsoankita@gmail.com Background: Vitamin D3 has shown immunomodulatory properties influencing cell signalling pathways in chronic respiratory disorders. There is limited evidence concerning the role of Vitamin D3 and its influence on the COVID-19 disease severity. This study aims to determine the association between Vitamin D3 levels and disease severity and possible outcomes. Methods: This prospective study included 80 hospitalised RT-PCR positive patients. Patients were stratified into two groups based on oxygen saturation (<90% and >90%) at admission. Vitamin D3 was stratified as deficient (<12 ng/ ml), insufficient (12-20 ng/ml) and sufficient (>20 ng/ml). Results: A total of 80 patients were included, 40 at room air (median age, 50; 62.5%male) and 40 on oxygen support (median age, 57; 65.8% male). Vitamin D3 deficiency was found in 22 (55%) patients on oxygen as compared to only 6 (15%) patients on room air (p<0.001). The mean vitamin D3 levels for patients on oxygen was significantly lower as compared to patients at room air (14.78 ± 10.33, 26.49 ± 19.06, respectively; p= 0.0009). Adverse outcome reported was more in vitamin D3 deficient patients (25% vs 11.3%). Mean Vitamin D3 among patients who died was less (14.3±9.90) as compared to those who survived (21.7±16.9), but not statistically significant (p= 0.18). Conclusion: Vitamin D3 deficiency showed significant association with COVID disease severity. Being one of the modifiable risk factors, early identification and corrective measure could alleviate a severe course of illness.

Institute of Pulmocare and Research, Kolkata, West Bengal, India. E-mail: sayoni.sengupta@gmail.com Background: The multisystem involvement of covid-19 lingers in post-covid phase. The significance of baseline resting pulse rate was looked for in long-covid relating to symptoms in acute phase, 2-chair test response, and echocardiography. Methods: Serial long-covid patients attending out-patient department were included. They were evaluated on demographic (age, height, weight, and BMI), characteristics, symptom score in acute phase (symptom severity in 0 to 5 scale X duration of symptoms), variables (pulse-rate and SpO2 changes) related to 2 chair test and resting Doppler echocardiography (LV ejection fraction, TSAPSE, left and right ventricular free wall GLS, and LV filling pressure. Two groups with pulse rate below or above 90/minute were compared. Results: The mean duration of acute illness for both the group is computed to be (118.44±95.95 vs. 152.77±102.25, p-value= 0.42) respectively. The baseline pulse rate were significantly different between those above (n=12) and below 90 (n=23) per minute (101±5.83 vs.72.85±8.14; p<0.0001); so is the post-exercise maximum pulse rate (p<0.004). Subjects with lower pulse rate had better height (p=0.05), weight (p=0.06), and higher anosmia (p=0.005) but lower total symptoms score (26.4±51.02 vs.29.66±66.12; p=0.008). The spirometric parameters (FVC, FEV1, FWV1/FVC) were better (although not significant) in those with lower pulse rate. The echocardiographic parameters as LVEF, TAPSE, LVFP were similar; the free wall GLS of both RV and LV were reduced in both the groups but that of RV (and LV were affected more in lower and higher pulse rate group respectively. Conclusion: Baseline pulse-rate in post covid subjects is likely related to neuro-inflammatory symptoms (anosmia) and poor LVGLS suggesting LV myocardial dysfunction.

Department of Respiratory Medicine, SMS Medical College, Jaipur, Rajasthan, India. E-mail: krishna.skumarpriya@gmail.com Background: Recurrent COVID-19 infection is a new entity and is underdiagnosed. Despite the improvement of our knowledge about this virus, it is still challenging and controversial whether all patients with SARS-CoV-2 infection will reactivate the illness and which risk factors predict eventual recurrence. Recurrence of COVID-19, whether reactivation or reinfection pose a major public health concern since it could significantly contribute to the spread of virus. Better understanding about this can improve our knowledge of the COVID-19 pathogenesis and ways to control the transmission. Case Study: A 41 year old male with no known comorbidities was admitted five times during a period of 7 months each time after being detected RTPCR positive for SARS-CoV-2 and more symptomatic than previously. He had no contact with other COVID-19 patients and was asymptomatic in between admissions. Despite this, he never developed antibodies against SARS-CoV-2. Later on, he was diagnosed with thymoma on biopsy of the anterior mediastinal mass. Patient's condition deteriorated on last hospitalization and he died, despite the treatment. Here we present an interesting case on multiple times recurrent COVID-19 infection, probably a case of reactivation and different plausible explanations on the role of thymoma. Conclusion: Acknowledging the potential of SARS-CoV-2 to cause recurrence is very important during the pandemic as a part of long term transmission mitigation. This case shows that previous infection does not guarantee complete immunity from COVID-19, especially in immunocompromised patients. Hence, despite the status of prior infection, vulnerable individuals who recovered from COVID-19 should be under surveillance. Elevated inflammatory markers are observed as common pathophysiological response to acute illness. High ferritin levels can cause pro-inflammatory changes and immune suppression. The aim of the study is to assess if ferritin can be used as an independent biomarker to predict severity in COVID 19. Methods: A cross sectional study was conducted at a tertiary care hospital from May 2021 to November 2021 and a convenience sample of 525 was included. The following variables were collected sociodemographic determinants, co-morbidities, clinical presentation, laboratory results, and durations of intensive care unit (ICU) and in-hospital stay. The data collected was entered into MS excel version 10 and statistically analysed using SPSS software.

Result: In the current study, 54.8% belong to age group 41-60 years, males were 63.5 % compared to 36.3% females. 32.4 % study subjects stayed for longer duration (>14 days) and 67.6% have raised serum ferritin levels (>250 ng/ ml), among them 29% have more than 1000ng/ml. longer duration of hospital stay was found to have statistically significant association with increased ferritin levels. Among study subjects having ferritin levels > 1000ng/ml, 64.7% stayed for longer duration (chi-square = 60.151, df =1, p=0.00). Mortality was found to be 29%. Conclusion: Increased ferritin levels in COVID 19 patients is associated with longer duration of hospital stay, ICU admissions and mortality. Serum ferritin is cost effective and accessible even at peripheral settings for better risk stratification, monitoring and timely intervention.

Institute of Chest Surgery, Medanta -The Medicity, Gurguram, Haryana, India. E-mail: mohanvenkateshpulle@gmail.com Objectives: This study aims at reporting the surgical outcomes of COVID Associated Pulmonary Mucormycosis (CAPM) with special emphasis on surgical mortality. This study also compares the surgical outcomes between Non-COVID Pulmonary Mucormycosis (NCPM) and CAPM.

Methods: This prospective observational study was conducted in a dedicated thoracic surgical unit in Gurugram over 18 months which includes 25 patients. An analysis of demography, perioperative variables including complications were carried out. Various parameters were analysed to assess the factors affecting mortality. Results: Out of 25 patients, male-female ratio was 16:9 (64%:36%), with a mean age of 54.8 years (range, 33-72 years). Diabetes was the most common predisposing factor in 17 patients (68%). A total of 8 patients (32%) were on supplemental oxygen (1-4 lit/min) at the time of surgery. Extent of surgery was non-anatomical wedge resection in 5 patients (20%), lobectomy/bi-lobectomy in 18 patients (72%) and pneumonectomy in 2 patients (8%). Commonest complication was prolonged air leak (> 7 days) in 5 patients (20%). There were 5 peri-operative deaths (20%), all due to persistent fungal sepsis. ECOG scale > 2 (P = <0.001) and pneumonectomy (P = 0.02) were the predictors of mortality. On comparison with NCPM, no difference in the postoperative complications (P = 1.00) and mortality (P = 1.00) was observed. infection with HRCT Thorax suggestive of moderate to severe COVID-19 pneumonia based on CT severity scores, were followed for a period of six months post discharge. They were treated with antivirals, anticoagulants, short course of steroids and empirical antibiotics. They were discharged with antifibrotics and were followed up monthly. An improvement in six minute walk test was observed in all patients, serial chest X-rays showing near complete resolution of fibrotic bands. HRCT Thorax was repeated at an interval of three months post discharge which also showed improvement in the fibrotic areas with a reduced CT Severity score. Discussion: Pulmonary fibrosis was a common finding in almost all patients who recovered from a severe COVID-19 infection. There was significant improvement in fibrosis scores 30 days, 60 days and 90 days after discharge, confirming that pulmonary fibrosis was likely to resolve post-COVID-19 infection. Meanwhile, in some cases, the fibrosis did not completely resolve within 90 days, and whether additional anti-fibrotic treatment could accelerate the process is worthy of further investigation. Conclusion: Radiological resolution of non-homogenous opacities over a period of time raises hope for complete recovery in the minds of patients as well as physicians. In the present series we report 3 patients who were presented with pneumothorax while having COVID-19 infection. Contrary to the presumed mechanism of pneumothorax, none of them had severe cough as a presenting symptom that could have caused alveolar rupture leading to air leak. The first patient had a fibrosed left lung secondary to old tuberculosis but presented with right sided pneumothorax and pneumomediastinum. The second patient had sequential development of bilateral pneumothorax. The third patient presented with isolated pneumomediastinum. The first two patients had a favorable outcome despite having severe COVID-19, unfortunately the third patient succumbed to his illness. Discussion: The present study is a reminder that an acute deterioration with hypoxia in a Covid-19 patient could indicate a pneumothorax which may occur even in the absence of severe cough. Therefore, pneumothorax may be a presenting feature in COVID-19. High vigilance is required during assessment of patients, as both share the common symptom of breathlessness and therefore can mimic each other. Conclusion: Pneumothorax is a known complication in COVID-19 and should be suspected in a patient who does not respond to treatment. 

Background: Pneumothorax has been noted to be a complication of covid19 pneumonia caused by SARS-COV2 requiring hospitalization and increasing mortality. Case Study: A series of 10 cases of spontaneous pneumothorax in patients with covid19 pneumonia either RTPCR positive or radiological positive admitted into a tertiary care centre from April 2021 to September 2021. Discussion: Of 10 cases of pneumothorax, 8 were confirmed covid19 positive by RTPCR and 2 were radiologically diagnosed based on CT imaging. None of them had previous lung disease, 2 were smokers and 1 had prolonged biomass fuel exposure. 3 of them were kept on NIV support and others required oxygen with facemask. All patients had moderate to severe disease with bilateral GGOs. All of them had acute onset of chest pain, drop in saturation and increased respiratory rate. All the patients were managed with ICD insertion and oxygen supplementation. Out 10 patients, 5 patients had favorable outcome and discharged and death occurred in 5 patients. Conclusion: Acute deterioration in a patient with covid19 pneumonia indicate a pneumothorax which may occur even in the absence of pre-existing lung disease and mechanical ventilation. Early diagnosis and management of this complication is necessary to prevent the risk of mortality. 

Background: Tuberculosis(TB) is one among the various respiratory pathologies affecting post-covid patients. We intend to describe clinico-radiological characteristics of tuberculosis in post-covid patients. Methods: Retrospective descriptive study, conducted at SDS TRC and RGICD, Bengaluru from May 2020 to November 2021 with inclusion criteria of Tuberculosis with history of COVID in last 6 months. Clinicoradiological characteristics of them were retrieved from medical records section. Results: 13 patients were included in our study. Male predominance (69%), with mean age of 50.7years noted. Patient with co-morbidity were 61.53%, majority were diabetics. 46% severe, 15%moderate covid cases received corticosteroids during covid illness and 38% were mild who didn't receive corticosteroids. Mean duration of TB diagnosis after covid was 2 months. 5 patients were diagnosed as pulmonary tuberculosis with cough, fever, weight loss as presentation, 6 presented with air-leak in which 4 had hydropneumothorax, 2 had pneumothorax with dyspnea as presentation and 2 had pleural effusion. 69% of chest radiograph revealed cavity. Rest showed nodules, consolidation. Bandim-TB score was assigned. 4 were mild and rest 11 were of moderate to severe category. AFB Sputum smear / CBNAAT-positive in 85% cases. Among 2 pleural effusions, pleural fluid CBNAAT was positive in 1 and in other biochemical analysis was suggestive of tuberculosis. 15% were Rifampicin resistant TB. All except 1 were newly diagnosed tuberculosis. 2 patients succumbed to the disease and rest were discharged on appropriate anti-tubercular regimen. Conclusion: Post-covid patients when presents with persistent or worsening respiratory symptoms, tuberculosis should be excluded especially in endemic countries like India. A total of 1000 COVID patients were taken in the order of their admission from Jan-May 2021. Monocyte count in the blood at the time of admission was collected. Ethical clearance was obtained from the institutional ethical committee. Results: Higher monocyte count was seen in the younger age group, particularly in Category B COVID-19 patients. Statistically significant association was found between low monocyte count and the disease severity and mortality in patients with COVID-19. Conclusion: It is inferred that monocytes proliferate to eliminate the viruses in mild patients, while the loss of monocytes in the critical patients suggest that innate immunity might be suppressed to a certain extent in critical COVID-19. Deviation in monocytes count from the normal is a valuable discriminator for diagnosis of COVID-19 and suitable anticipator of overall spectrum of adverse consequences. with renal involvement had higher overall mortality compared with patients without renal involvement. Adverse short-term outcomes of renal involvement were associated with severity of COVID-19 pneumonia Conclusion: AKI could be used as a clinical characteristic in severity classification and risk stratification. Further investigation of the underlying mechanism of renal disease in COVID-19 would be needed to clarify possible therapeutic targets.

To study the correlation of clinical, radiological and laboratory parameters with the outcome in covid-19 patients treated with HFNC

Madras Medical College, Chennai, Tamil Nadu, India. E-mail: abi22vasan@yahoo.com Background: High-flow nasal cannula (HFNC) has been reported to be effective in improving oxygenation in COVID pneumonia patients with hypoxemic respiratory failure. This observational study aims to correlate the clinical, radiological and laboratory parameters with the outcome of HFNC therapy. Materials and Methods: Clinical data including symptoms, age, gender, respiratory rate, heart rate and Spo2 on admission, comorbidities, CT chest, laboratory data such as NLR, serum Ferritin, CRP, D-dimer were correlated with HFNC therapy outcome. Results: 152 patients with COVID pneumonia treated with high flow nasal cannula oxygen therapy were studied. Among them, 98(64.5%) patients had a successful outcome and 54 (35.5%) patients had a failure outcome. The mean age was 58 years and the majority were male (62.5%). Breathlessness was the major symptom found in 132 (86.8%) patients, followed by fever (78.9%), cough (57.9%), myalgia (34.2%), and GI symptoms(9.9%). There was a statistically significant association between CT severity at the time of admission and outcome (p-value 0.0002). D-dimer and ferritin were significantly associated with poor outcome (p-value 0.0005) of which D-dimer had more sensitivity and specificity (90.8% & 90.7%). Conclusion: Our data suggest that HFNC plays an important role in patients with COVID-19 related hypoxemic respiratory failure. There was a statistically significant association between CT severity, clinical and laboratory parameters with the HFNC outcome. Methods: This diagnostic accuracy study was conducted on suspected COVID-19 SARI patients and were divided into two groups based on the results of RT-PCR for COVID-19 and to minimise false-negative RT-PCR in the control group patientshaving HRCT-thorax CORADS-5 were excluded, and the accuracy of different serum biomarker in predicting cases withpositive RT-PCR was evaluated using the area under the ROC curve (AUC),In thisstudy, AUC 0.9 to 1 was defined as excellent accuracy, 0.8 to0.9 as very good, 0.7 to 0.8 as good, 0.6 to 0.7 as sufficient, 0.5to 0.6 as bad, and < 0.5 as poor(useless test Conclusions: Healthcare workers are exposed to increased risk in the execution of their duties and require support to secure their wellbeing. Policies, systems for early detection of sleep and psychological problems, training, preparedness and efficacy in crisis management are suggested to reduce and prevent the occurrence of these problems among HCWs.

Department of Pulmonary Medicine, GMC, Patiala, Punjab, India. E-mail: saikapankur@gmail.com

Background: COVID-19 and dengue infection both are caused by single-stranded RNA viruses of the families' coronaviridae and flaviviridae respectively. Both diseases share various clinical and laboratory parameters, making them difficult to distinguish from one another. In these times of covid-19 where dengue is already a public health concern, this co-infection poses great threat to already burdened healthcare system. Case Study: So, here we report a case of 76 year old male with complaints of high grade fever and dyspnea for 2 days diagnosed with COVID-19 who was simultaneously diagnosed with dengue infection and later died of ARDS and sepsis delineating the rarity and severity of this coinfection. Discussion: In the tropical counties, there is an emerging threat of dengue-covid co-infection. They have overlapping clinical presentations, also share several laboratory parameters like elevated liver enzymes, leukopenia and thrombocytopenia. Aggressive fluid resuscitation has a key role in dengue which may worsen oxygenation in COVID-19 patients. Also, the use of LMWH in COVID-19 settings can have a devastating effect in the setting of thrombocytopenia in case of dual infection. Conclusion: As we wait for more data, it is emphasized the need for early detection of the dual infection by testing all covid 19 patients for dengue in endemic areas as the disease can be more severe or one pathology can be misdiagnosed for the other. Introduction: Many countries have seen a two-wave pattern in reported cases of coronavirus disease-19 during the 2020 pandemic and the dynamic changes of D-dimer and Hs-CRP levels during disease progression to evaluate their value for thrombo-embolic events and severity of disease during wave I and wave II of COVID 19 disease in critically ill patients became significant. Methods: In this study using data from two equal periods of 5 months, the first wave, between 20th July to 30th Nov and the second, between March to 30th July, characteristics are compared of hospitalised patients in Intensive Care Unit. Results: In this study, we reported 50 confirmed COVID 19 disease patients from wave I and wave II respectively. Patients in the second wave were younger and the duration of hospitalization and case fatality rate were higher than those in the first wave. These results might help to understand the characteristics of the second wave and the behaviour and danger of SARS-CoV-2 with the risk of thrombosis and bleeding.

The second wave was more severe and yet more data required to study seasonal trend and severity of different COVID-19 strain. The impact of the severity of the COVID-19 on potential long-term consequences is currently not well documented. With a 6-minute walk test, we followed up on 30 patients who were COVID 19 survivors with varied CT-Severity scores. The aim was to correlate the CT-Severity score with 6 minute walk distance and percentage desaturation. Methods: Data of post COVID-19 patients who presented to our hospital from January to June 2021 were collected. Patients who had undergone a HRCT scan during their admission time were chosen and followed up with 6 minute walk test and data was analyzed.

(cough, breathlessness, throat pain, nasal discharge, fever, body-ache, weakness, diarrhoea, constipation, pedal/finger swelling, headache, expectoration. anosmia, and loss of taste) that they suffered from. The weight/impact of a symptom was derived by multiplying the duration of symptoms (in days) with the severity (in Likert scale; "0" to "5"; "0"=none and "5"=maximum possible symptoms). The data was analysed statistically using unpaired 't-test' and 'chi-square test' to compare between the two covid-19 waves.

Result: 185 and 222 subjects' data were included for the 1 st and the 2 nd waves of covid-19 respectively. The gender ratio was similar but the mean age was significantly lower in the victims of the second wave (56.17±13.64, 51.32±15.59; p=0.0017). As regards the symptom-frequency, fever (p=0.0154), constipation (p=0.0243), headache (p=0.0014), anosmia (p=<0.0001) and loss of taste (p=0.0009) were significantly worse in the 2 nd wave. The symptom severity of cough (p=0.0184), throat pain (p=0.039), mild weakness (p=0.0063), anosmia (p=0.0004) and loss of taste (p=0.0026) were also higher in the 2 nd wave of Covid-19.

Conclusion: It appears that each wave of the pandemic was distinct as regards the symptomatology. Such peculiarity in the clinical dynamics of Covid-19 needs to be noticed and followed in future.

Differential diagnosis of cavitary lung lesions

Department of Pulmonary Medicine, Rajarajeshwari Medical College and Hospital, Kambipura, Karnataka, India. E-mail: manjarirajagopalan@yahoo.com Background: The greatest difficulty during the COVID pandemic was in effective triaging of patients. A new scoring system was developed by our center in order to provide a holistic assessment of the illness including systemic manifestations. This study was to evaluate the effectiveness of the scoring system in comparison to CURB 65, the most commonly used screening tool for prognostic assessment of pneumonia. Aim: To compare CURB 65 and Covid Severity Score Predictor 50 in measuring prognosis in patients with COVID 19 illness Methods: 150 Patients with COVID 19 illness were enrolled . The COVID severity score PReDiCTOR 50 was designed in our set up during the pandemic to assess prognosis of disease. This is retrospective analysis to compare the efficacy of the predictor against CURB 65 in assessing prognosis of COVID 19 illness using receiver operator characteristic curves and associated area under the curve. \ Results: We studied 150 patients with COVID 19 illness. 35 died and 103 were discharged. The ability to predict ICU admission was higher for our scoring system (AUC 0.875 ) as compared to CURB 65 ( AUC 0.83). Conclusion: The Covid SeveriTy Score PReDiCTOR 50 was found to be more effective in prognostic assessment of COVID 19 illness in comparison to CURB 65, indicating the importance of holistic assessment of COVID. Background: Post COVID-19 symptoms and diseases appeared on many survivors from COVID-19 which are similar to that of the post-severe acute respiratory syndrome (SARS) fatigue. Hence, the study aims to investigate and characterize the manifestations which appear after eradication of the coronavirus infection and its relation to disease severity. Methods: About 428 COVID 19 survivors were included in the study, they were questioned and data was collected regarding their post covid manifestations and presence of any comorbidities. Results: Amongst the 428 patients 15% of them had post COVID symptoms and fatigue and cough were predominantly seen. Conclusion: All subjects recovered from COVID-19 should undergo long-term monitoring for evaluation and treatment of symptoms and conditions that might be precipitated with the new coronavirus infection.

Background: COVID-19 vaccines shows good efficacy in the course of COVID19 pandemic, but some people still become infected with SARS-CoV-2 even after vaccination. The present study is to identify the disease progression in SARS -CoV2 infection among post-vaccinated patients with first and second dose of vaccinations. Methods: This is a retrospective observational study of 108 vaccinated, hospitalized confirmed covid-19 patients at tertiary care hospital from July,2021 to August,2021. Patients data in terms of vaccine status, type of vaccine, duration from last dose, inflammatory markers , comorbidities, severity of illness are collected and analyzed.Result: Total 500 patients of which 21% (108) got vaccinated. 68% (74) patients received single dose of vaccination and remaining 32% (34) patients completed two doses. 74% (80) patients were diagnosed through RAT/RTPCR and 26% (28) patients based on HRCT-Chest. 59% (64) patients had co-morbidities of which 65% (42) patients taken single dose and 35% (22) patients completed two doses. 35% (38) patients required O2 support, out of which 73% (28) has taken single dose and 27% (10) completed two doses. Average duration of hospital stay is 7 days in non oxygen dependent patients, 13 days in O2 / NIV support patients. Total 8%(8)deaths were reported of which 50%(4) received single dose of vaccination and 50%(4)completed two doses. Conclusion: In vaccinated patients disease severity is mild. In patients with co-morbidities who received single dose, requirement of O2/NIV was more when compared to patients who received both doses. Mortality is seen in patients with co-morbidities, even with complete vaccination.

Department of Respiratory Medicine, Andhra Medical College, Visakhapatnam, Andhra Pradesh, India. E-mail: 127renu@gmail. com Background: SARS-COV-2 has caused morbidity and mortality at an unprecedented scale globally. During recovery, several patients are found to have functional impairment and radiological abnormalities. Case Study: An observational study done on 54 post-covid patients attending our center during July to November. A detailed history, radiology and clinical data during acute and post-covid visit were analyzed. Aims: To document various post-covid complications, assessing risk factors for complications Discussion: Mean age group of presentation 49.2years, mean time of follow-up presentation is 66.4 days. Incidence is higher in males (64.8%) than females (35%),83.3% are having one or more existing comorbidities during acute covid mainly diabetes 61%, hypertension 38%, Both in 25%, copdin 7.4%, tuberculosis in 3.7%, HIV in 1.85 %. About 79.6% had more than 3 weeks of hospital stay,46.2% are on NIV support during acute covid. Majority of post-covid patients came with dyspnea -75.9%, cough -74%, fatigue -31.4%, productive cough -14%, fever -9%, chest pain -7%. Resting hypoxia is seen in 29.6% of patients. Of post-covid patients,88% presented with pulmonary fibrosis,12.9% with pnemothorax,12.9%with lung cavity,3.6%with necrotizing pneumonia and 1.8%with lung abscess. Both pneumothorax and fibrosis are seen in 9.25%, both cavity and fibrosis in 5.5%. post-covid pulmonary cavities (7) were due to tuberculosis, klebsiella, pseudomonas, E. coli, fungal itology.Comparativelyradiological improvement is seen in 86% of the patients Background: Tracheoesophageal fistula (TEF) is a rare condition that can be congenital or acquired. Patients of COVID-19 remain intubated for prolonged periods that can give rise to a multitude of complications. We came across a case where patient develop TEF after 7 days of tracheostomy. Case Study: 34 years female admitted with Covid pneumonia. Patient required ICU care for respiratory distress, required intubation. Patient was treated with standard treatment and kept on controlled ventilation. Patient underwent tracheostomy on day 12 of intubation. On day 17 of patient had an episode of sudden severe respiratory distress, desaturation, hypotension tachycardia not generating tidal volumes and rising peak pressures on ventilator. Patient developed bilateral tension pneumothorax immediately bilateral intercostal drainage tubes insertion done and patient settled. On day 19 patient had persistent cough with RT feeds coming through tracheostomy tube and site. Suspecting TEF CT neck with thorax was done. A rent is seen in the tracheal and esophageal walls close to the bulb of tracheostomy tube. with a TEF. Long tracheostomy tube was inserted as conservative management. Discussion: COVID-19 patients with severe pneumonia may require and remain on prolonged mechanical ventilation. The sudden deterioration of respiratory status, gastric distension and food particles in intubated tube are suspicious to TEF. Conclusion: Early tracheostomy can prevent some complications of prolonged intubation. If a patient develops sudden desaturation, gastric distension and food particles in tracheostomy tube then TEF should always be in the differential diagnosis.

Department of Pulmonary Medicine, JIPMER, Puducherry, India. E-mail: sivaselvisaran33@gmail.com Background: On 21 December 2019, a pneumonia-like outbreak of an unknown cause was found to be emerging in Wuhan, China. The Clinical presentations of COVID 19 infection may vary from asymptomatic to multiorgan failure. Most of the infected people have recovered from the disease, this recovery could be confirmed by negative RTPCR or absence of symptoms for several days. But some patients have been found to have symptoms at post discharge follow-up. Methods: A descriptive study was started on August 2021 at a tertiary care hospital after institutional ethics committee clearance. All patients who tested positive for COVID-19(RTPCR or Rapid antigen test (RAT) diagnosed or radiographically diagnosed COVID-19(CORADS 5) attending post COVID clinic were recruited. The proportion of people developing post COVID 19 manifestations, and Results: In the 30 patients, whose data was analyzed, 19 were male and 11 were female. Of the 30 patients whose reports were analyzed, 15 (50%) had CT-Severity score between 6-14 (moderate). Only 10 (33.3%) patients had CT-Severity score more than 15 (severe) and of them only 3 had desaturation more than 10% on 6MWT. While only 3 patients had desaturation between 5-10%, majority of the patients (24/30) had less than 5% desaturation on 6MWT. More than half the patients (17/30; 56.7%) walked more than 350 metres in 6 minutes, while 11 patients walked between 150-350 metres and only 2 patients walked less than 150 metres. Conclusion: In COVID-19 survivors, we conclude that CT-Severity has minimal effect on exercise tolerance.

Background: A patient presenting with cavitatory lung lesions offers a variety of differential diagnosis to the treating chest physician. It varies from acute and chronic infections, systemic illnesses and malignancy. [1] Arriving at a proper diagnosis and proceeding to next step of management is very challenging. Patient improved with antifungal therapy. Discussion: Case 2 required surgical intervention, while case 1 and case 3 improved with medical management. A multidisciplinary team was involved in the management. Early diagnosis is the cornerstone for management. Conclusion: Each patient of post COVID cavitatory lung lesion should be assessed properly and to be treated by individualised approach rather than a generalised approach. Newer antifungals and combination antifungals should be further explored along with surgical management.

Department of Pulmonology and Sleep Medicine, Max Smart Super Speciality Hospital, Saket, New Delhi, India. E-mail: drmrigankajuneja@gmail.com Background: 70-90 % of the adult population carries latent cytomegalovirus (CMV), which may be reactivated by inflammation and immune suppression. CMV reactivation has been seen in up to one-third of critically ill patients, and is associated with worse clinical outcomes. Here, the authors present two challenging cases, wherein the management of severe COVID-19 disease was complicated by CMV pneumonia. Case Reports: Our patients presented with severe COVID-19 pneumonia with acute respiratory distress syndrome and were admitted in the intensive care unit (ICU). The patients received immunosuppressive therapy, either tocilizumab or methylprednisolone pulse therapy. Both the patients had a prolonged hospital stay, and showed an initial improvement followed by clinical deterioration, with recurrence of fever, worsening respiratory failure, and development of consolidations on CT thorax. A thorough work up for opportunistic infections revealed CMV infection. Both patients were treated with intravenous Ganciclovir and showed marked improvement. Discussion: The use of steroids and other immunomodulatory therapies in the treatment of severe COVID-19 disease, along with immune suppression caused by severe COVID-19 itself, predisposes patients to reactivation of CMV. Furthermore, CMV reactivation is associated with a longer ICU length of stay, prolonged mechanical ventilation, increased risk of secondary infections, and mortality. Conclusion: These cases highlight the importance of considering CMV disease as a differential diagnosis in critically ill patients with COVID-19 with unexplained worsening, especially in the setting of immunomodulatory therapies, as early treatment may prevent adverse clinical outcomes and mortality. from acute COVID 19 remain speculative. Chronic lung disease including IPF is a risk factor for poorer prognosis in COVID 19 infection. Case Study: A 52-year-old male patient presented to emergency department with history of dyspnea on and off for past 6 months increased over last two days, cough with expectoration for past 2 months. Eight months back he was treated for COVID 19 pneumonia with dexamethasone and maximal oxygen requirement of 2L via nasal cannula. CT chest showed diffuse GGO's in bilateral upper and lower lobes with CT severity score of 20/25. Patient was discharged with no oxygen requirement with saturation of 96% on room air. On arrival to the hospital, patient was tachypneic and in type 1 respiratory failure, requiring 10L of oxygen. CT chest showed honeycombing with consolidation and traction bronchiectasis. Discussion: Advanced fibrosis and poor lung function are associated with severe disease and poorer prognosis in COVID 19 infection. CD 209L receptors has been implied in the pathogenesis of progressive ILD in COVID 19 infection. Conclusion: Early detection of potential cases of post-COVID 19 pulmonary fibrosis may give a chance to prevent or at least modify such disabling complication. Background: SARS -COV-2 has presented with varied symptoms and a number of factors determine clinical outcome. While hypoxemic respiratory failure remains main cause of morbidity and mortality, a hyperinflammatory state induced endothelial injury and hypercoagulability leading to thromboembolism also is a leading cause of mortality. Case Sudy: A 60-year-old diabetic, hypertensive, nonsmoker, male presented with complaints of cough, fever and breathlessness since 3 days. Patient presented with tachypnea and maintaining saturation of 85% on room air, CT severity score was 13/25. Patient was treated in ICU with Noninvasive ventilation, prophylactic Enoxaparin, Remdesivir and steroids. Patient's respiratory status was deteriorating and was intubated, kept on mechanical ventilator and later tracheostomy was done. During the course of illness patient developed pain over right foot which progressed to gangrene and ischemia over left foot .CT-Aortogram done showed complete occlusion of infra-renal abdominal aorta. Discussion: Patient developed progressive elevation of D-dimer even after thromboprophylaxis with enoxaparin. However gangrene progression was irreversible once set in, even though patient was switched over to high dose anticoagulants, with antiplatelet along with Phosphodiesterase inhibitor, implying that high degree of coagulation cascade disruption is potentially irreversible. Conclusion: To start increased dose of initial thromboprophylaxis in patient with high CT severity. Background: With increasing number of patients recovered, significant detrimental long-term effects of post-COVID-19 infection has been recognized.CAT score in COPD is a great tool to assess symptoms severity, same may be used in post COVID patients. Objective: 1.Assess the use of CAT scores in post COVID-19 patients.2.Use CAT score as a predictor of long term effects. Methods: An observational study conducted between October 2020-November 2021. RT-PCR/TruNAT COVID-19 positive post COVID patients were included,their symptoms severity were evaluated based on CAT score. Patients with high CAT score were evaluated for long term effects. Results: Out of 89 patients, 50 (56%) were male,39 (44%) were female. 66(74.15%) smokers, 15(16.8%) non-smokers. 51 (57.3%) were COPD, 31(34.83%) Asthma, 62 (69.7%) Diabetic, 45(50.5%) Hypertensive patients. On 1 month follow-up, >30 CAT score in 11(12.3%), 33 (37%) had CAT score 21-30, 27(30.33%) CAT score 10-20, 18(20.22%) CAT <10.3months, CAT >30 in 5 (5.6%), CAT 21-30 in 19(21.3%), CAT 10-20 in 22 (24.7%), <10 CAT was in 43 (48.3%).6 months, CAT >30 in 6 (6.14%), CAT 21-30 in 13 (14.6%), CAT 10-20 in 33(37.7%), CAT <10 in 37 (41.5%).Patients CAT >10, spirometry revealed FVC <60%, should be evaluated for ILD by CT scan after 8 weeks and for long term pulmonary fibrosis. Conclusion: CAT score, effective tool in COPD find its use to assess post COVID-19 patients. It's a ready -made tool, less cost-expenditure, easy to use in rural ,urban set up to assess patients symptom ,long term effect.

The first and the second waves of Covid-19; difference in clinical dynamics as regards the symptoms-an appraisal